Table 3.
Outcomes | Predictors | Univariate Regression Analysis |
Multivariate Regression Analysis | ||||
---|---|---|---|---|---|---|---|
Correlation Coefficient | p-Value | Standardized Regression Coefficient |
p-Value | Variance Inflation Factor |
R2 Final Multivariate Model |
||
Orientation construct | Duration of maternal plasma viremia | 0.10 | 0.7651 | −0.92 | 0.0112 | 3.80 | 0.85 |
Peak maternal plasma viral load |
−0.21 | 0.5193 | |||||
Fraction of vRNA -positive cotyledons | −0.21 | 0.4479 | 0.72 | 0.0197 | 3.10 | ||
DENV immunity (PRNT90) | 0.08 | 0.7654 | |||||
Infarctions/total cotyledons |
−0.09 | 0.7603 | 0.49 | 0.0153 | 1.30 | ||
Fetal head circumference trajectory | 0.01 | 0.9827 | 0.47 | 0.0169 | 1.20 | ||
Fetal biparietal diameter growth trajectory | −0.39 | 0.1331 | |||||
Total placental weight | 0.29 | 0.2974 | 1.08 | 0.0008 | 1.50 | ||
Birth weight | 0.14 | 0.6117 | |||||
Focus subgroup of Orientation construct |
Duration of maternal plasma viremia | 0.01 | 0.9736 | −1.07 | 0.0171 | 3.8 | 0.76 |
Peak maternal plasma viral load |
−0.21 | 0.5198 | |||||
Fraction of vRNA -positive cotyledons | −0.26 | 0.3471 | 0.84 | 0.029 | 3.1 | ||
DENV immunity (PRNT90) | 0.07 | 0.7967 | |||||
Infarctions/total cotyledons |
−0.07 | 0.8174 | 0.49 | 0.0395 | 1.3 | ||
Fetal head circumference trajectory | 0.06 | 0.8223 | 0.5 | 0.0342 | 1.2 | ||
Fetal biparietal diameter growth trajectory | −0.38 | 0.1417 | |||||
Total placental weight | 0.31 | 0.2591 | 1.04 | 0.003 | 1.5 | ||
Birth weight | 0.04 | 0.8821 | |||||
Visual Orientation subgroup of Orientation construct | Duration of maternal plasma viremia | −0.1 | 0.7684 | −0.63 | 0.0003 | 7.90 | 0.98 |
Peak maternal plasma viral load |
0.05 | 0.8793 | |||||
Fraction of vRNA -positive cotyledons | −0.40 | 0.1428 | 0.30 | 0.0018 | 4.60 | ||
DENV immunity (PRNT90) | −0.03 | 0.9124 | 0.44 | 0.0001 | 2.10 | ||
Infarctions/total cotyledons |
0.18 | 0.5189 | 0.17 | 0.0078 | 3.40 | ||
Fetal head circumference trajectory | −0.53 | 0.0331 * | |||||
Fetal biparietal diameter growth trajectory | −0.78 | 0.0004 * | −0.77 | <0.0001 | 3.40 | ||
Total placental weight | 0.48 | 0.0729 | |||||
Birth weight | 0.13 | 0.6220 | 0.57 | 0.0002 | 4.80 | ||
Visual tracking subgroup of Orientation construct | Duration of maternal plasma viremia | 0.12 | 0.7141 | No significant predictors | |||
Peak maternal plasma viral load |
−0.06 | 0.8449 | |||||
Fraction of vRNA -positive cotyledons | −0.11 | 0.6921 | |||||
DENV immunity (PRNT90) | −0.05 | 0.8572 | |||||
Infarctions/total cotyledons |
−0.29 | 0.2990 | |||||
Fetal head circumference trajectory | −0.15 | 0.5875 | |||||
Fetal biparietal diameter growth trajectory | −0.4 | 0.1244 | |||||
Total placental weight | 0.44 | 0.0971 | |||||
Birth weight | 0.19 | 0.4732 | |||||
Auditory orientation subgroup of Orientation construct |
Duration of maternal plasma viremia | 0.21 | 0.5101 | −1.8 | 0.0011 | 8.1 | 0.94 |
Peak maternal plasma viral load |
−0.32 | 0.3148 | −0.77 | 0.0045 | 3.2 | ||
Fraction of vRNA -positive cotyledons | −0.05 | 0.8646 | 1.88 | 0.0008 | 7.4 | ||
DENV immunity (PRNT90) | 0.17 | 0.5205 | |||||
Infarctions/total cotyledons |
0.07 | 0.8151 | |||||
Fetal head circumference trajectory | 0.32 | 0.2323 | 0.57 | 0.0066 | 2.2 | ||
Fetal biparietal diameter growth trajectory | −0.07 | 0.8054 | −0.94 | 0.0012 | 2.3 | ||
Total placental weight | 0.05 | 0.8643 | |||||
Birth weight | 0.04 | 0.8884 | 1.27 | 0.0011 | 4 | ||
Motor maturity & activity construct | Duration of maternal plasma viremia | 0.57 | 0.0541 | 0.52 | |||
Peak maternal plasma viral load |
0.40 | 0.1925 | 0.56 | 0.0577 | 1.2 | ||
Fraction of vRNA -positive cotyledons | 0.43 | 0.1084 | |||||
DENV immunity (PRNT90) | 0.26 | 0.3248 | |||||
Infarctions/total cotyledons |
−0.14 | 0.6248 | −0.75 | 0.0776 | 2.6 | ||
Fetal head circumference trajectory | −0.01 | 0.9567 | 0.83 | 0.0332 | 1.9 | ||
Fetal biparietal diameter growth trajectory | −0.12 | 0.6707 | −1.08 | 0.0458 | 3.9 | ||
Total placental weight | 0.62 | 0.0128 * | |||||
Birth weight | 0.30 | 0.2648 | |||||
Sensory responsiveness construct | Duration of maternal plasma viremia | −0.24 | 0.4620 | No significant predictors | |||
Peak maternal plasma viral load |
0.19 | 0.5567 | |||||
Fraction of vRNA -positive cotyledons | −0.1 | 0.7102 | |||||
DENV immunity (PRNT90) | −0.02 | 0.9483 | |||||
Infarctions/total cotyledons |
0.21 | 0.4580 | |||||
Fetal head circumference trajectory | −0.44 | 0.0872 | |||||
Fetal biparietal diameter growth trajectory | −0.05 | 0.8541 | |||||
Total placental weight | −0.08 | 0.7905 | |||||
Birth weight | 0.02 | 0.9309 | |||||
State control construct | Duration of maternal plasma viremia | −0.66 | 0.0187 * | −0.51 | 0.0877 | 1.00 | 0.19 |
Peak maternal plasma viral load |
−0.63 | 0.0283 * | |||||
Fraction of vRNA -positive cotyledons | −0.41 | 0.1240 | |||||
DENV immunity (PRNT90) | −0.24 | 0.3743 | |||||
Infarctions/total cotyledons |
−0.05 | 0.8693 | |||||
Fetal head circumference trajectory | −0.01 | 0.9828 | |||||
Fetal biparietal diameter growth trajectory | −0.07 | 0.8034 | |||||
Total placental weight | −0.28 | 0.3147 | |||||
Birth weight | −0.07 | 0.8029 |
* p-value < 0.05 in univariate regression analysis.